Vaxcellbio (CEO Je-Jung Lee,  MD, PhD ), a biotechnology company specializing in immuno-oncology, announced ,that it has successfully obtained an Australian patent for its core proprietary technology, titled “COMPOSITION CONTAINING FEEDER CELL FOR PROLIFERATING NATURAL KILLER CELL.”

This patented technology utilizes feeder cells transduced to express B7H6, CD137L, IL-15, and IL-15Rα genes, enabling the mass expansion of high-purity, highly cytotoxic natural killer (NK) cells. By applying a differentiated feeder cell-based platform, the company has significantly improved cell proliferation speed, purity, and yield, thereby enhancing both the productivity and consistency of NK cell-based therapeutics and achieving stable large-scale manufacturing.

Vaxcellbio has sequentially secured this patent in Japan (April 2025), Korea (July 2025), and Australia (October 2025), demonstrating the originality and competitiveness of its NK cell expansion platform across leading biotech markets. Patent examinations are also underway in the United States, Europe, China, Canada, and Hong Kong.

CEO Je-Jung Lee said, “The completion of our Australian patent registration, following Korea and Japan, validates the global originality and reliability of Vaxcellbio’s NK cell manufacturing technology,” adding, “Based on this patented core feeder cell technology, we plan to further advance our next-generation CAR (Chimeric Antigen Receptor)-NK cell and gene therapy production platforms and actively pursue global technology licensing and international co-development opportunities.”

In addition to this milestone, Vaxcellbio has recently obtained multiple core technology patents related to cell and gene therapies, including BCMA (B-cell Maturation Antigen) CAR-MIL (Marrow-Infiltrating Lymphocyte), MIL culture and activation, and monobody-based CAR technologies. With a total of 16 domestic and international patents, the company continues to strengthen its intellectual property portfolio.  This latest Australian patent is expected to serve as another key step toward establishing Vaxcellbio’s NK cell manufacturing technology as a global standard.

Key Takeaways

• Vaxcellbio has secured an Australian patent for its proprietary NK cell expansion technology, following successful registrations in Korea and Japan, further strengthening its global intellectual property portfolio in advanced cell manufacturing.

• The patented feeder cell platform—engineered to express B7H6, CD137L, IL-15, and IL-15Rα—enables rapid, high-yield, and high-purity NK cell expansion, significantly improving the productivity, consistency, and scalability of NK cell-based immunotherapies.

• Building on this core technology, Vaxcellbio plans to advance next-generation CAR-NK and gene therapy platforms, while accelerating global technology licensing and international co-development initiatives.

• CEO Je-Jung Lee said, “The completion of our Australian patent registration, following Korea and Japan, validates the global originality and reliability of Vaxcellbio’s NK cell manufacturing technology,” adding, “Based on this patented core feeder cell technology, we plan to further advance our next-generation CAR (Chimeric Antigen Receptor)-NK cell and gene therapy production platforms and actively pursue global technology licensing and international co-development opportunities.”